Contact Us
Find A Doctor

Geographic Atrophy Trial

Geographic Atrophy Trial

Enrollment Status

Open Enrollment


A phase 2/3 study to evaluate the use of ORACEA® (40mg doxycycline) capsule daily for 24 months vs. placebo as treatment for Geographic Atrophy.


  • 20/20 - 20/400 in the study eye
  • Ages 55 years and older.
  • geographic atrophy secondary to non-exudative age-related macular degeneration in at least one eye (study eye)
  • Geographic atrophy lesions of ≥ 0.5 and ≤ 7.0 MPS disc areas


  • History of or active presence of choroidal neovascularization secondary to exudative age-related macular degeneration in the study eye and non-study eye requiring any treatment within 12 months prior to Day 0 or expected to require treatment for the duration of the study
  • Prior treatment for non-exudative age-related macular degeneration
  • History of vitreoretinal surgery, corneal transplant, or laser photocoagulation in the study eye

Enrollment in the Study

Katy Tai, CRC: 212-979-4251, 

Contact Us

Richard Rosen, MD, Principal Investigator

Address310 E. 14th StreetNew York, NY 10003

Katy Tai, CRCTel: 212-979-4251

View all locations